3SOF

Quote from: fous on October 20, 2006, 12:05:12 PM
Well i missed the double bagger lol. Lets see if i cant make at least 20% on this sucker this time. Im in at 4.10. I see the potential for a similar chart to ACOR for SIGA. Who knows we might still have another bag to make

-fous

Quote from: Se7en on October 20, 2006, 01:02:55 PM
I'm also back in @ 4.13$.

Seeing you guys back in, makes me more confident about holding on to this tiger.
GLTA

Was able to get in again at 4.04. Seems bulls are fighting for control now

I don't think its time to get in yet, the 9sma is being left behind because of the gap up it needs to catch up first before deciding to get in.....the 9sma must catch up not the price so it's better to wait for now

it will be interesting if SIGA will act as ACOR 

have a nice weekend
cheers
Oliver

 

good one boatguy 

Seems Terliso was right we bought too soon.

jorgegr

I'm back in 15,000 @ 3.57.

Quote from: stocks2watch2 on October 23, 2006, 01:49:02 PM
I'm back in 15,000 @ 3.57.

congrats stocks2watch2,
better entry price as mine (4.17$ average)

cheers
Oliver

why I am so confident, that I will have huge profit with SIGA shares again part 1

why I am so confident, that I will have huge profit with SIGA shares again part 2

why I am so confident, that I will have huge profit with SIGA shares again part 3



cheers
Oliver

please check also the video:
http://www.kval.com/news/4448787.html?video=YHI&t=a

Smallpox Breakthrough

Story Published: Oct 20, 2006 at 6:12 PM PST
By Cathryn Stephens
Watch the Video
It's potentially a major breakthrough in bioterrorism defense. A Corvallis biotech lab has developed the first drug ever to show 100% percent protection against the smallpox virus.
It's a disease that was eradicated decades ago, but smallpox is considered one of the top biowarfare threats today. This new drug could wipe out that threat.
SIGA-246 promises to safeguard the population from a smallpox bio-warfare attack, according to company officials in Corvallis.

"We think it's huge," said Dennis Hruby, the chief scientific officer with SIGA Technologies. "It was a horrible dread disease, and having a drug on the shelf that will prevent this from ever happening again I think is a gigantic insurance policy that we're all going to be very happy about." Hruby says the drug proved 100% effective in a Centers for Disease Control and Prevention test, protecting monkeys from the smallpox virus with no side effects.
"For this kind of drug you want a really safe drug because you're talking about a drug to prevent a disease that doesn't exist and so safety has to be very high on the list," said Hruby.
Inside the SIGA lab in Corvallis there are 50 researchers, including 16 PhD's. Along with the smallpox project, they're also researching drugs to treat Ebola and Dengue Fever.
"I get pressure all the time, move the company back east, move to San Francisco. This has just been an outstanding place to work, next to Oregon State, it's easy to recruit good people, it's a really good environment," said Hruby.
Hruby believes SIGA's smallpox drug will be just as effective on humans, both as preventative and as treatment, should it be needed. The main buyer of the drug would be the federal government. "In a real world scenario what's going to happen is if you have a population you're not going to know who's been exposed, who hasn't and for how long, so what you'd like to do is treat simultaneously with drug and vaccine and protect everybody," said Hruby.

Testing on SIGA-246 is continuing, but the U.S. government will likely be able to stockpile it before it receives final FDA approval under the Department of Homeland Security's Project Bioshield.
SIGA hopes to submit its new drug application for approval by the the Food and Drug Administration in early 2009.

http://www.kval.com/news/4448787.html




cheers
O.

last but not least:
Healthy development
CASEY CAMPBELL/Gazette-Times
At Siga Technologies' Corvallis research labs, Eric Stavale works on a possible treatment for the Dengue virus. Siga got a big cash infusion last week after announcing progress on an experimental smallpox treatment.
Siga Technologies finds quick payoff from test of smallpox remedy

By BENNETT HALL
Gazette-Times business editor

It's been a long and bumpy road, but the finish line may be in sight for Siga Technologies in its journey toward profitability.
Like many — if not most — small drug-discovery companies, Siga has burned through millions of dollars and posted year after year of losses as it tried to bring a developmental treatment to market. After a successful animal trial announced last week, however, the company could be on the verge of scoring a major coup with the first effective treatment for smallpox.
"In the biodefense area, smallpox is the number one concern, and we would expect this is going to be our big product," said Dennis Hruby, Siga's chief scientific officer and a microbiology professor at Oregon State University.
Smallpox was eradicated in nature 30 years ago but is considered a potential terrorist threat, and no proven treatment for the deadly virus exists. The Defense Department and other federal agencies funded the latest test, conducted on monkeys at a secure Centers for Disease Control facility in Atlanta.
Siga claims its drug, a once-daily pill called Siga-246, showed "100 percent protection" against the smallpox virus, both before and after exposure. The drug previously passed a human safety trial.
Additional tests are needed before the company can request approval from the Food & Drug Administration, but the Defense Department is footing the bill with a $16.5 million grant.
The news of a successful test triggered a financial windfall for Siga, which employs 50 people at its Corvallis research labs.
On Wednesday, the day the test results were announced, the company's stock price more than doubled, shooting up to $4.54 a share after languishing at around $1 for most of the last year.
On Thursday, the company completed a $9 million private stock placement with some of its longtime institutional investors. Five hedge funds — Iroquois Master Fund, Cranshire Capital, Omicron Master Trust, Rockmore Investment Master Fund and Smithfield Fiduciary — bought the issue, consisting of 2 million shares of common stock at $4.54 a share. They also received warrants for an additional 1 million shares exercisable at $4.99 a share.

"It gave us the opportunity to bring in some cash quickly at a nice price," said chief financial officer and acting CEO Tom Konatich, who's been with the biotech firm for eight years. "Our balance sheet right now is about as strong as it's been during my tenure."
The stock placement caps a resurgence for Siga, which had entered a merger agreement last spring with an East Coast biotech company and faced delisting from the Nasdaq exchange this summer as its market capitalization slipped.

Now, with its cash reserves recharged and a smallpox drug marching toward approval, the merger is off and Siga is on the rebound.
"Siga's a significantly different company today than it was in February and March," Konatich said by phone from the company's New York headquarters Friday. "We will be lobbying and negotiating with various agencies of the federal government for a sale of the drug."

Konatich declined to speculate on when a deal to supply the drug might be reached or what it might be worth to Siga. But he did say that various industry estimates make it clear that the potential market for smallpox treatments is a lucrative one.

"It's in the hundreds of millions of dollars, if not more," he said.

Other potential markets await overseas, particularly in Europe. Hruby has been invited to Geneva to make a presentation to the World Health Organization's advisory council, which he hopes will help spread the word about Siga's research.

Hruby said Siga-246 can treat monkeypox and related viral diseases, and the firm is also pursuing drug candidates for a range of other exotic viruses.

"There's two things: There's biodefense, and there's emerging diseases," Hruby said. "Hopefully, we'll never need it for biodefense. But it's nice to have a drug like this on the shelf."

http://www.gazettetimes.com/articles/2006/10/23/news/business/1mon01siga.txt

Great info la-onda! <applaud>

It was a good day for SIGA, hopefully the bleeding has stopped now ...